Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 13/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.63 |
| ▸ | CDK2 | P24941 | 3/20 | 0.63 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.63 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17172576 | 1.00 | GLS (1.00) | GLSCCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL15725006 | 1.00 | GLS (1.00) | GLSCCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL15724974 | 1.00 | GLS (1.00) | GLSCCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL15724979 | 1.00 | GLS (1.00) | GLSCCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL15724989 | 0.95 | GLS (1.00) | GLSRECQLKMT2A | |
| SCHEMBL15724994 | 0.95 | GLS (1.00) | GLSRECQLKMT2A | |
| SCHEMBL20392486 | 0.95 | GLS (1.00) | GLSRECQLKMT2A | |
| SCHEMBL15724986 | 0.95 | GLS (1.00) | GLSRECQLKMT2A | |
| SCHEMBL21325757 | 0.93 | GLS (0.86) | GLSCCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL18836867 | 0.92 | GLS (0.85) | GLSCCNE1CDK2CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3697764-A1 | GLUTAMINASE INHIBITOR THERAPY | Board Of Regents, The University Of Texas System (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10689375-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| WO-2019079632-A1 | GLUTAMINASE INHIBITOR THERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20190084976-A1 | COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2019-03-21 | — | — | US | disclosed |
| EP-3456719-A1 | COMPOUNDS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-2922850-B1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20150291576-A1 | COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-15 | — | — | US | disclosed |
| US-20150291576-A1 | COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-15 | — | — | US | disclosed |
| US-9029531-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029531-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| WO-2014079136-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES AS GLUTAMINASE INHIBITORS FOR TREATING CANCERS THEREOF | AGIOS PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014079150-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014079011-A1 | HETEROCYCLIC COMPOUNDS FOR INHIBITING GLUTAMINASE AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140142081-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142081-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291576-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | GLS 1/4885CCNE1 1203/4885CDK2 581/4885 |
| US-20190084976-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | GLS 1/4885CCNE1 2109/4885CDK2 711/4885 |
| US-20140142081-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | GLS 1/4885CCNE1 2109/4885CDK2 711/4885 |
| US-10689375-B2 | Compounds and their methods of use | GLS, GLS2, GLUL | GLS 1/4885CCNE1 2109/4885CDK2 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.